Carl Zeiss Meditec AG AFX.DE · Stock Open Carl Zeiss Meditec AG in new tab
Carl Zeiss Meditec AG Analysis (AFX.DE)
Is Carl Zeiss Meditec AG a good investment? Carl Zeiss Meditec AG (AFX.DE) is currently trading at 31.06 EUR. Market analysts have a consensus price target of 27.15 EUR. This suggests the asset is currently trading above analyst expectations.
In terms of valuation, the stock trades at a P/E ratio of 21.30. This valuation is generally in line with the broader market.
Earnings Schedule: Carl Zeiss Meditec AG is expected to release its next earnings report on Aug. 6, 2026. The market consensus estimate for Forward EPS is 1.48.
For income investors, Carl Zeiss Meditec AG pays a dividend yield of 1.79%. With a payout ratio of 41%, the dividend appears sustainable.
Investor FAQ
Does Carl Zeiss Meditec AG pay a dividend?
Yes, it pays an annual dividend of 0.55 EUR (1.79% yield).
What asset class is Carl Zeiss Meditec AG?
Carl Zeiss Meditec AG is classified as a Stock. You can compare it against 4 other assets in the "Related Symbols" list on this page.
When is the next earnings date?
The next earnings date is projected to be Aug. 6, 2026. The company currently has a trailing EPS of 1.37.
Company Profile
Carl Zeiss Meditec AG operates as a medical technology company in Germany, rest of Europe, North America, and Asia. It operates in two segments, Ophthalmology and Microsurgery. The Ophthalmology segment offers products and solutions for the diagnosis and treatment of chronic eye diseases, including slit lamps, refractometers, and tonometers; optical coherence tomography and fundus cameras for retina examination; functional glaucoma diagnostic devices (perimeters); surgical ophthalmology products comprising surgical microscopes, biometers, and phacoemulsification and vitrectomy equipment; intraocular lenses for cataract surgery; and systems and consumables for laser eye surgery that include the VISUMAX femtosecond laser, which enables minimally invasive correction of vision defects using lenticular extraction, as well as digital products for the storage, analysis, and sharing of clinical data. The Microsurgery segment provides products and solutions for minimally invasive surgical treatments, including surgical visualization, interoperative radiotherapy, interoperative pathology, special surgical instruments, and digital solutions, as well as the ZEISS Tumor Workflow, a cross-product workflow solution. It serves physicians in various fields and hospitals. The company has a strategic collaboration with Envision Health Technologies Inc. to help advance glaucoma care through gamified virtual reality technology. The company was founded in 1846 and is headquartered in Jena, Germany. Carl Zeiss Meditec AG operates as a subsidiary of ZEISS Group.
| Year | Total Dividends |
|---|---|
| ▸2027 |
0.55 EUR
|
| March 31, 2027 (estimated) | 0.5500 |
| ▸2026 |
0.55 EUR
|
| March 31, 2026 | 0.5500 |
| ▸2025 |
0.60 EUR
|
| March 31, 2025 | 0.6000 |
| ▸2024 |
1.10 EUR
|
| March 26, 2024 | 1.1000 |
| ▸2023 |
1.10 EUR
|
| March 27, 2023 | 1.1000 |
| ▸2022 |
0.90 EUR
|
| April 4, 2022 | 0.9000 |
| ▸2021 |
0.50 EUR
|
| June 1, 2021 | 0.5000 |
| ▸2020 |
0.65 EUR
|
| Aug. 11, 2020 | 0.6500 |
| ▸2019 |
0.55 EUR
|
| March 22, 2019 | 0.5500 |
| ▸2018 |
0.55 EUR
|
| April 13, 2018 | 0.5500 |
| ▸2017 |
0.42 EUR
|
| June 2, 2017 | 0.4200 |
| ▸2016 |
0.38 EUR
|
| April 7, 2016 | 0.3800 |
| ▸2015 |
0.40 EUR
|
| March 19, 2015 | 0.4000 |
| ▸2014 |
0.45 EUR
|
| March 5, 2014 | 0.4500 |
| ▸2013 |
0.40 EUR
|
| March 6, 2013 | 0.4000 |
| ▸2012 |
0.30 EUR
|
| March 12, 2012 | 0.3000 |
| ▸2011 |
0.33 EUR
|
| April 13, 2011 | 0.3300 |
| ▸2010 |
0.18 EUR
|
| March 5, 2010 | 0.1800 |
| ▸2009 |
0.18 EUR
|
| May 20, 2009 | 0.1800 |
| ▸2008 |
0.16 EUR
|
| March 10, 2008 | 0.1600 |
| ▸2007 |
0.14 EUR
|
| March 12, 2007 | 0.1400 |
| ▸2006 |
0.16 EUR
|
| March 13, 2006 | 0.1600 |
| Name | Payment Date | Status | Amount |
|---|---|---|---|
| Carl Zeiss Meditec AG | Mar 31, 2026 | Paid | 0.55 EUR |
| Split Date | Split Ratio to 1 |
|---|---|
| Oct. 24, 2006 | 1.37 |
Community Discussion